|
|
|
|
|
Neuro-Oncology
Reviews
|
|
|
|
Volume
27 Number 16
10 June 2025
|
|
|
|
Home
>
Publications
>
Neuro-Oncology
Reviews >
Volume
27, Year 2025 >
Number 16,
10 June
|
|
|
|
|
|
Chen AG, Do TH, Chen KY, Zhu P.
Robust
and Specific Association Between Seizure at Presentation and
Improved Survival in Patients With Primary Brain Tumors.
Discov
Med. 2025 Jun;37(197):984-993. doi:
10.24976/Discov.Med.202537197.88. PMID:
40485516. Review˰ ˍ
|
|
|
|
Maitra A, Miciaccia M, Mandorino M, Armenise D, Baldelli OM,
Ferorelli S, Papusha L, Druy A, Perrone MG, Scilimati A.
Decoding
Gene Expression Changes in Cerebral Tumors: Before and After
Radiotherapy.
Med
Res Rev. 2025 Jun 1. doi:
10.1002/med.22122. PMID:
40452178. Review. ˍ
>>>
Diffuse midline glioma
|
|
|
|
Gong AD, Dang DD, Awan O, Mugge L, Yokoi H, Cohen AL, Moores L.
Pediatric-type high-grade glioma of
the spinal cord in the molecular era: institutional case series
and updated systematic review of the literature.
Childs
Nerv Syst. 2025 Jun 2;41(1):200. doi:
10.1007/s00381-025-06856-8. PMID:
40455242. Review˰ ˍ
|
|
|
|
Liu Y, Su C, Wei X, Wei N, Qian Q, Xu Z.
Prospects
and applications of NK therapy in the treatment of gliomas
(Review).
Oncol
Rep. 2025 Jun 3;54(2):88. doi:
10.3892/or.2025.8921. PMID:
40476557. Review. ˍ
|
|
|
|
Song Z, Yang C, Gu J, Qu R, Xie Y, Guo Y, Nong X, Chen Z, Wang Z.
The hotspots and publication trends in
glioblastoma and CAR-T immunotherapy: A bibliometric analysis.
Hum
Vaccin Immunother. 2025 Jun 3;21(1):2509483. doi:
10.1080/21645515.2025.2509483. PMID:
40460258. Bibliometric analysis. ˍ
|
|
|
|
Feng XL, Su G, Wu QH, Jia Q, Zhang ZC.
Research
progress of galectins in glioma.
Discov
Oncol. 2025 Jun 4;16(1):1003. doi:
10.1007/s12672-025-02318-4. PMID:
40467873. Review. ˍ
|
|
|
|
Shah S, Lucke-Wold B.
Cell-Intrinsic
and Cell-Extrinsic Therapeutic Targets in Glioblastoma: Overcoming
Resistance Through Tumor Microenvironment Modulation and Precision
Medicine.
World
Neurosurg. 2025 Jun 4:124142. doi:
10.1016/j.wneu.2025.124142. PMID:
40480545. Review. ˍ
|
|
|
|
Li H, Wu Y, Chen Y, Lv J, Qu C, Mei T, Zheng Y, Ye C, Li F, Ge S,
Yao A, Jia L.
Overcoming temozolomide
resistance in glioma: recent advances and mechanistic insights.
Acta
Neuropathol Commun. 2025 Jun 5;13(1):126. doi:
10.1186/s40478-025-02046-4. PMID:
40468460. Review. ˍ
|
|
|
|
Doniselli FM, Ramos J, Hilario A, Opancina V, van der Hoorn A,
Castellano A, van der Molen AJ, Quattrocchi CC, Yousry T, Rovira
À; ESMRMB-GREC Working Group; ESNR.
Recommendations
on the use of gadolinium-based contrast agents in the diagnosis
and monitoring of common adult intracranial tumours.
Eur
Radiol. 2025 Jun 6. doi:
10.1007/s00330-025-11646-6. PMID:
40478344. Recommendations˰
ˍ
|
|
|
|
Qiu Y, Huang S, Peng L, Yang L, Zhang G, Liu T, Yan F, Peng X.
The Nasal-Brain Drug Delivery Route:
Mechanisms and Applications to Central Nervous System Diseases.
MedComm
(2020). 2025 Jun 6;6(6):e70213. doi:
10.1002/mco2.70213. PMID:
40487748. Review. ˍ
|
|
|
|
Rudà R, Bruno F, Pellerino A, Pronello E, Soffietti R.
Low-grade IDH-mutant
gliomas: from standard post-surgical treatments to novel IDH
inhibitors.
Expert
Opin Pharmacother. 2025 Jun 6:1-13. doi:
10.1080/14656566.2025.2516617. PMID:
40479721. Review˰ ˍ
|
|
|
|
He J, Yan X, Hu S.
Glioma stem cells:
drivers of tumor progression and recurrence.
Stem
Cell Res Ther. 2025 Jun 7;16(1):293. doi:
10.1186/s13287-025-04352-z. PMID:
40483525. Review. ˍ
|
|
|
|
|
|
|
|
|
|
|
|
|